These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Novel Therapies for Thyroid Autoimmune Diseases. Fallahi P; Ferrari SM; Elia G; Nasini F; Colaci M; Giuggioli D; Vita R; Benvenga S; Ferri C; Antonelli A Expert Rev Clin Pharmacol; 2016 Jun; 9(6):853-61. PubMed ID: 26900630 [TBL] [Abstract][Full Text] [Related]
4. The Th1 chemokine MIG in Graves' ophthalmopathy. Gonnella D Clin Ter; 2019; 170(5):e368-e372. PubMed ID: 31612195 [TBL] [Abstract][Full Text] [Related]
5. Chemokines in thyroid autoimmunity. Ferrari SM; Paparo SR; Ragusa F; Elia G; Mazzi V; Patrizio A; Ghionzoli M; Varricchi G; Centanni M; Ulisse S; Antonelli A; Fallahi P Best Pract Res Clin Endocrinol Metab; 2023 Mar; 37(2):101773. PubMed ID: 36907786 [TBL] [Abstract][Full Text] [Related]
6. Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone. Antonelli A; Ferrari SM; Fallahi P; Piaggi S; Paolicchi A; Franceschini SS; Salvi M; Ferrannini E Metabolism; 2011 Feb; 60(2):277-83. PubMed ID: 20206950 [TBL] [Abstract][Full Text] [Related]
7. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. Antonelli A; Rotondi M; Ferrari SM; Fallahi P; Romagnani P; Franceschini SS; Serio M; Ferrannini E J Clin Endocrinol Metab; 2006 Feb; 91(2):614-20. PubMed ID: 16303841 [TBL] [Abstract][Full Text] [Related]
8. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. Antonelli A; Ferrari SM; Fallahi P; Frascerra S; Santini E; Franceschini SS; Ferrannini E J Clin Endocrinol Metab; 2009 May; 94(5):1803-9. PubMed ID: 19276231 [TBL] [Abstract][Full Text] [Related]
9. [CXCR3 and CXCL10 in autoimmune thyroiditis]. Ruffilli I; Ferrari SM; Colaci M; Ferri C; Politti U; Antonelli A; Fallahi P Clin Ter; 2014; 165(3):e237-42. PubMed ID: 24999582 [TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptor α agonists modulate Th1 and Th2 chemokine secretion in normal thyrocytes and Graves' disease. Antonelli A; Ferrari SM; Frascerra S; Corrado A; Pupilli C; Bernini G; Benvenga S; Ferrannini E; Fallahi P Exp Cell Res; 2011 Jul; 317(11):1527-33. PubMed ID: 21565188 [TBL] [Abstract][Full Text] [Related]
11. Differential modulation of CXCL8 versus CXCL10, by cytokines, PPAR-gamma, or PPAR-alpha agonists, in primary cells from Graves' disease and ophthalmopathy. Ferrari SM; Ragusa F; Paparo SR; Nasini F; Nardi M; Franceschini SS; Fallahi P; Antonelli A Autoimmun Rev; 2019 Jul; 18(7):673-678. PubMed ID: 31059842 [TBL] [Abstract][Full Text] [Related]
12. [The alpha chemokine "Interferon gamma-induced protein 10" (IP-10) in Graves' disease]. Mancusi C; Di Domenicantonio A; Politti U; Giuggioli D; Antonelli A; Ferri C; Fallahi P Clin Ter; 2014; 165(2):e174-80. PubMed ID: 24770830 [TBL] [Abstract][Full Text] [Related]
13. [The alpha chemokine "Interferon gamma-induced protein 10" (IP-10) in Graves' disease and Graves'ophthalmopathy]. Di Domenicantonio A; Politti U; Giuggioli D; Antonelli A; Ferri C; Fallahi P Clin Ter; 2014; 165(3):e230-6. PubMed ID: 24999581 [TBL] [Abstract][Full Text] [Related]
14. β (CCL2) and α (CXCL10) chemokine modulations by cytokines and peroxisome proliferator-activated receptor-α agonists in Graves' ophthalmopathy. Antonelli A; Ferrari SM; Frascerra S; Ruffilli I; Pupilli C; Bernini G; Sellari-Franceschini S; Gelmini S; Ferrannini E; Fallahi P J Endocrinol; 2012 May; 213(2):183-91. PubMed ID: 22378921 [TBL] [Abstract][Full Text] [Related]
15. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy. Antonelli A; Rotondi M; Fallahi P; Romagnani P; Ferrari SM; Barani L; Ferrannini E; Serio M Clin Endocrinol (Oxf); 2006 Feb; 64(2):189-95. PubMed ID: 16430719 [TBL] [Abstract][Full Text] [Related]
16. Novel therapies for thyroid autoimmune diseases: An update. Ferrari SM; Fallahi P; Elia G; Ragusa F; Camastra S; Paparo SR; Giusti C; Gonnella D; Ruffilli I; Shoenfeld Y; Antonelli A Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101366. PubMed ID: 31813786 [TBL] [Abstract][Full Text] [Related]
17. Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. Antonelli A; Fallahi P; Rotondi M; Ferrari SM; Romagnani P; Grosso M; Ferrannini E; Serio M Eur J Endocrinol; 2006 May; 154(5):651-8. PubMed ID: 16645011 [TBL] [Abstract][Full Text] [Related]
18. Role for interferon-gamma inducible chemokines in endocrine autoimmunity: an expanding field. Rotondi M; Lazzeri E; Romagnani P; Serio M J Endocrinol Invest; 2003 Feb; 26(2):177-80. PubMed ID: 12739748 [TBL] [Abstract][Full Text] [Related]
19. IP-10 in autoimmune thyroiditis. Ruffilli I; Ferrari SM; Colaci M; Ferri C; Fallahi P; Antonelli A Horm Metab Res; 2014 Aug; 46(9):597-602. PubMed ID: 24977661 [TBL] [Abstract][Full Text] [Related]
20. The Th1 chemokine MIG in Graves' Disease: a narrative review of the literature. Giusti C Clin Ter; 2019; 170(4):e285-e290. PubMed ID: 31304517 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]